TY  - JOUR
AU  - Beckmann, Janna
AU  - Petzold, Moritz
AU  - Betzler, Felix
AU  - Ströhle, Andreas
AU  - Bendau, Antonia
AU  - Dusemund, Carla
AU  - Petzold, Gabor C
AU  - Meisel, Andreas
AU  - Hoffmann, Sarah
TI  - Anxiety in Myasthenia Gravis Patients Throughout the COVID-19 Pandemic-Prevalence, Risk Factors, and Association With Vaccination Status.
JO  - Brain and behavior
VL  - 15
IS  - 9
SN  - 2162-3279
CY  - Malden, Mass.
PB  - Wiley
M1  - DZNE-2025-01099
SP  - e70878
PY  - 2025
AB  - A high prevalence of COVID-19-related anxiety was observed among the general population during the COVID-19 pandemic. Patients with myasthenia gravis (MG) might be at higher risk for COVID-19-related anxiety due to immunosuppressive therapy in the majority of cases and risk of myasthenic exacerbation in case of an infection. This prospective longitudinal study assessed COVID-19-related anxiety in MG patients over 2 years of the pandemic and its association with MG-specific factors (e.g., disease severity, immunosuppressive medication) and with vaccination status.A three-wave longitudinal online survey was conducted from May 2020 to February 2022, including a total of 648 adult MG patients. Descriptive, univariate, and multivariate analyses were performed to assess COVID-19-related and MG-related anxiety, associated MG-specific factors, and association with vaccination status.COVID-19-related anxiety was frequent, with the most pronounced fear being risk for one's own health (overall 83.9
KW  - Humans
KW  - Myasthenia Gravis: psychology
KW  - Myasthenia Gravis: epidemiology
KW  - Myasthenia Gravis: drug therapy
KW  - Myasthenia Gravis: complications
KW  - COVID-19: psychology
KW  - COVID-19: epidemiology
KW  - Female
KW  - Male
KW  - Anxiety: epidemiology
KW  - Anxiety: etiology
KW  - Anxiety: psychology
KW  - Middle Aged
KW  - Risk Factors
KW  - Prevalence
KW  - Adult
KW  - Aged
KW  - Longitudinal Studies
KW  - Prospective Studies
KW  - Vaccination: psychology
KW  - Vaccination: statistics & numerical data
KW  - Immunosuppressive Agents: therapeutic use
KW  - Immunosuppressive Agents: adverse effects
KW  - SARS-CoV-2
KW  - autoimmune disease (Other)
KW  - corona (Other)
KW  - fear (Other)
KW  - immunosuppressive treatment (Other)
KW  - Immunosuppressive Agents (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:40958409
C2  - pmc:PMC12441002
DO  - DOI:10.1002/brb3.70878
UR  - https://pub.dzne.de/record/281352
ER  -